U.S. Cannabis Companies Struggle With Institutional Capital, While Europe Thrives, Says Expert

The U.S. cannabis industry is facing a persistent roadblock — access to institutional capital.

Despite the market’s growth, many cannabis companies struggle to secure the financial backing needed to sustain operations and expand, according to William Muecke, co-founding managing member of Artemis Growth Partners and upcoming Benzinga Cannabis Capital Conference speaker.

“The biggest issue for valuation and for companies to be repriced multiple lines in the sector is the involvement in institutional capital,” Muecke said in a recent interview.

He noted that while the industry continues to grow, the lack of access to traditional capital markets remains a significant obstacle.

Struggles with Securing Capital

Muecke highlighted that the problem isn’t with consumer …

Full story available on Benzinga.com